{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T23:56:33Z","timestamp":1776124593358,"version":"3.50.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The emergence of novel variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) underscores the need to investigate alternative approaches to prevent infection and treat patients with coronavirus disease 2019. Here, we report the preclinical efficacy of NL-CVX1, a de novo decoy that blocks virus entry into cells by binding with nanomolar affinity and high specificity to the receptor-binding domain of the SARS-CoV-2 spike protein. Using a transgenic mouse model of SARS-CoV-2 infection, we showed that a single prophylactic intranasal dose of NL-CVX1 conferred complete protection from severe disease following SARS-CoV-2 infection. Multiple therapeutic administrations of NL-CVX1 also protected mice from succumbing to infection. Finally, we showed that infected mice treated with NL-CVX1 developed both anti-SARS-CoV-2 antibodies and memory T cells and were protected against reinfection a month after treatment. Overall, these observations suggest NL-CVX1 is a promising therapeutic candidate for preventing and treating severe SARS-CoV-2 infections.<\/jats:p>","DOI":"10.1093\/infdis\/jiad135","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T13:35:50Z","timestamp":1686317750000},"page":"723-733","source":"Crossref","is-referenced-by-count":5,"title":["De Novo Human Angiotensin-Converting Enzyme 2 Decoy NL-CVX1 Protects Mice From Severe Disease After Severe Acute Respiratory Syndrome Coronavirus 2 Infection"],"prefix":"10.1093","volume":"228","author":[{"given":"Maria","family":"Rebelo","sequence":"first","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa , Lisboa , Portugal"}]},{"given":"Cong","family":"Tang","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa , Lisboa , Portugal"}]},{"given":"Ana R","family":"Coelho","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa , Lisboa , Portugal"}]},{"given":"Carlos","family":"Lab\u00e3o-Almeida","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa , Lisboa , Portugal"}]},{"given":"Matthias M","family":"Schneider","sequence":"additional","affiliation":[{"name":"Yusuf Hamied Department of Chemistry, University of Cambridge , Cambridge , United Kingdom"}]},{"given":"Laurie","family":"Tatalick","sequence":"additional","affiliation":[{"name":"Laurie Tatalick Consulting , Redmond, Washington , USA"}]},{"given":"Pedro","family":"Ruivo","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa , Lisboa , Portugal"}]},{"given":"Marta Pires","family":"de Miranda","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa , Lisboa , Portugal"}]},{"given":"Andreia","family":"Gomes","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa , Lisboa , Portugal"}]},{"given":"T\u00e2nia","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Histopathology Unit, Champalimaud Research , Lisboa , Portugal"}]},{"given":"Matthew J","family":"Walker","sequence":"additional","affiliation":[{"name":"Neoleukin , Seattle, Washington , USA"}]},{"given":"Hannes","family":"Ausserwoeger","sequence":"additional","affiliation":[{"name":"Yusuf Hamied Department of Chemistry, University of Cambridge , Cambridge , United Kingdom"}]},{"given":"J","family":"Pedro Simas","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa , Lisboa , Portugal"},{"name":"Cat\u00f3lica Biomedical Research and Cat\u00f3lica Medical School, Universidade Cato\u0301lica Portuguesa , Lisboa , Portugal"}]},{"given":"Marc","family":"Veldhoen","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa , Lisboa , Portugal"}]},{"given":"Tuomas P J","family":"Knowles","sequence":"additional","affiliation":[{"name":"Yusuf Hamied Department of Chemistry, University of Cambridge , Cambridge , United Kingdom"}]},{"given":"Daniel-Adriano","family":"Silva","sequence":"additional","affiliation":[{"name":"Neoleukin , Seattle, Washington , USA"}]},{"given":"David","family":"Shoultz","sequence":"additional","affiliation":[{"name":"Neoleukin , Seattle, Washington , USA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6594-8917","authenticated-orcid":false,"given":"Gon\u00e7alo J L","family":"Bernardes","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa , Lisboa , Portugal"},{"name":"Yusuf Hamied Department of Chemistry, University of Cambridge , Cambridge , United Kingdom"}]}],"member":"286","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"2023091519581536200_jiad135-B1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023091519581536200_jiad135-B2","doi-asserted-by":"crossref","first-page":"2027160","DOI":"10.1080\/21645515.2022.2027160","article-title":"The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review","volume":"18","author":"Mohammed","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"2023091519581536200_jiad135-B3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"2023091519581536200_jiad135-B4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.15585\/mmwr.mm7034e3","article-title":"Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant\u2014National Healthcare Safety Network","volume":"70","author":"Nanduri","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023091519581536200_jiad135-B5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by COVID-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"2023091519581536200_jiad135-B6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"2023091519581536200_jiad135-B7","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat Microbiol"},{"key":"2023091519581536200_jiad135-B8","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.abe0075","article-title":"De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2","volume":"370","author":"Linsky","year":"2020","journal-title":"Science"},{"key":"2023091519581536200_jiad135-B9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","article-title":"SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function","volume":"21","author":"Winkler","year":"2020","journal-title":"Nat Immunol"},{"key":"2023091519581536200_jiad135-B10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-020-2943-z","article-title":"COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice","volume":"589","author":"Zheng","year":"2021","journal-title":"Nature"},{"key":"2023091519581536200_jiad135-B11","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/eji.202048970","article-title":"Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset","volume":"50","author":"Figueiredo-Campos","year":"2020","journal-title":"Eur J Immunol"},{"key":"2023091519581536200_jiad135-B12","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1002\/cpmc.100","article-title":"SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup","volume":"57","author":"Stadlbauer","year":"2020","journal-title":"Curr Protoc Microbiol"},{"key":"2023091519581536200_jiad135-B13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-04441-6","article-title":"SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters","volume":"603","author":"Halfmann","year":"2022","journal-title":"Nature"},{"key":"2023091519581536200_jiad135-B14","doi-asserted-by":"crossref","first-page":"763292","DOI":"10.3389\/fimmu.2021.763292","article-title":"Longitudinal cytokine profile in patients with mild to critical COVID-19","volume":"12","author":"Ling","year":"2021","journal-title":"Front Immunol"},{"key":"2023091519581536200_jiad135-B15","doi-asserted-by":"crossref","first-page":"10344","DOI":"10.3390\/ijms231810344","article-title":"Role of innate and adaptive cytokines in the survival of COVID-19 patients","volume":"23","author":"Monserrat","year":"2022","journal-title":"Int J Mol Sci. MDPI"},{"key":"2023091519581536200_jiad135-B16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cyto.2012.05.020","article-title":"Functions of IL-15 in anti-viral immunity: multiplicity and variety","volume":"59","author":"Verbist","year":"2012","journal-title":"Cytokine"},{"key":"2023091519581536200_jiad135-B17","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s12276-021-00592-0","article-title":"Type I and III interferon responses in SARS-CoV-2 infection","volume":"53","author":"Kim","year":"2021","journal-title":"Exp Mol Med"},{"key":"2023091519581536200_jiad135-B18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cytogfr.2020.06.008","article-title":"IL-15 immunotherapy is a viable strategy for COVID-19","volume":"54","author":"Kandikattu","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"2023091519581536200_jiad135-B19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Monk","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2023091519581536200_jiad135-B20","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front Immunol"},{"key":"2023091519581536200_jiad135-B21","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023091519581536200_jiad135-B22","doi-asserted-by":"crossref","DOI":"10.1101\/2020.09.14.296442","article-title":"Microfluidic antibody affinity profiling for in-solution characterisation of alloantibody\u2014HLA interactions in human serum","volume-title":"BioRxiv [Preprint: not peer reviewed]. 3 November 2020. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2020.09.14.296442v2","author":"Schneider"},{"key":"2023091519581536200_jiad135-B23","doi-asserted-by":"crossref","first-page":"e202101270","DOI":"10.26508\/lsa.202101270","article-title":"Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma","volume":"5","author":"Schneider","year":"2022","journal-title":"Life Sci Alliance"},{"key":"2023091519581536200_jiad135-B24","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","article-title":"Monoclonal antibody therapies against SARS-CoV-2","volume":"22","author":"Focosi","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023091519581536200_jiad135-B25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.abd9909","article-title":"De novo design of picomolar SARS-CoV-2 miniprotein inhibitors","volume":"370","author":"Cao","year":"2020","journal-title":"Science"},{"key":"2023091519581536200_jiad135-B26","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.chom.2021.06.008","article-title":"Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease","volume":"29","author":"Case","year":"2021","journal-title":"Cell Host Microbe"},{"key":"2023091519581536200_jiad135-B27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10989-021-10339-0","article-title":"In-Silico design of a novel tridecapeptide targeting spike protein of SARS-CoV-2 variants of concern","volume":"28","author":"Rajpoot","year":"2021","journal-title":"Int J Pept Res Ther"},{"key":"2023091519581536200_jiad135-B28","doi-asserted-by":"crossref","first-page":"1022006","DOI":"10.3389\/fmicb.2022.1022006","article-title":"Resistance profile and mechanism of severe acute respiratory syndrome coronavirus-2 variants to LCB1 inhibitor targeting the spike receptor-binding motif","volume":"13","author":"Wu","year":"2022","journal-title":"Front Microbiol"},{"key":"2023091519581536200_jiad135-B29","first-page":"taac109","article-title":"Duration of immune protection of SARS-CoV-2 natural infection against reinfection.","volume-title":"J Travel Med","author":"Chemaitelly","year":"2022"},{"key":"2023091519581536200_jiad135-B30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2203965","article-title":"Effects of previous infection and vaccination on symptomatic Omicron infections","volume":"387","author":"Altarawneh","year":"2022","journal-title":"N Engl J Med"},{"key":"2023091519581536200_jiad135-B31","first-page":"2050","article-title":"Structural diversity of the SARS-CoV-2 Omicron spike","volume-title":"Mol Cell","author":"Gobeil","year":"2022"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad135\/50518329\/jiad135.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/6\/723\/51608283\/jiad135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/6\/723\/51608283\/jiad135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T19:58:45Z","timestamp":1694807925000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/6\/723\/7190325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,5]]},"published-print":{"date-parts":[[2023,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad135","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,15]]},"published":{"date-parts":[[2023,6,5]]}}}